Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 06.05.2019 3 AJR Am J Roentgenol 1 Am J Clin Oncol 1 BMC Cancer 2 Cancer 1 Clin Cancer Res 4 Eur Urol 2 Int J Radiat Oncol Biol Phys 2 J Nucl Med 2 J Urol 2 Lancet Oncol 2 Nat Rev Urol 4 Oncogene 1 Proc Natl Acad Sci U S A 4 Prostate 1 Urol Int 3 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. FELKER ER, Raman SS, Shakeri S, Mirak SA, et al
   Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer.
   AJR Am J Roentgenol. 2019 Apr 30:1-6. doi: 10.2214/AJR.18.20836.
   PubMed     Text format     Abstract available
   
   
2. CHATTERJEE A, He D, Fan X, Antic T, et al
   Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study.
   AJR Am J Roentgenol. 2019 Apr 30:1-10. doi: 10.2214/AJR.18.20702.
   PubMed     Text format     Abstract available
   
   
3. LAWHN-HEATH C, Flavell RR, Behr SC, Yohannan T, et al
   Single-Center Prospective Evaluation of (68)Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.
   AJR Am J Roentgenol. 2019 Apr 30:1-8. doi: 10.2214/AJR.18.20699.
   PubMed     Text format     Abstract available
   
   

   
   Am J Clin Oncol

4. TAKU N, Narayan V, Wang X, Vapiwala N, et al
   Prevalence, Predictors, and Implications for Appropriate Use of Active Surveillance Management Among Black Men Diagnosed With Low-risk Prostate Cancer.
   Am J Clin Oncol. 2019 Apr 29. doi: 10.1097/COC.0000000000000547.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

5. LI T, Sun X, Chen L
   Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function.
   BMC Cancer. 2019;19:87.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

6. NIK-AHD F, Howard LE, Eisenberg AT, Aronson WJ, et al
   Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.
   Cancer. 2019 Apr 29. doi: 10.1002/cncr.32141.
   PubMed     Text format     Abstract available
   
   
7. JOHNSON DC, Yang JJ, Kwan L, Barsa DE, et al
   Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection.
   Cancer. 2019 May 1. doi: 10.1002/cncr.32170.
   PubMed     Text format     Abstract available
   
   

   
   Clin Cancer Res

8. KULP SK, Chen CS, Wang DS, Chen CY, et al
   Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.
   Clin Cancer Res. 2019;25:2940.
   PubMed     Text format    
   
   

   
   Eur Urol

9. GNANAPRAGASAM VJ, Barrett T
   The Quest for the Optimal Prostate Biopsy Regime for the 21st Century.
   Eur Urol. 2019;75:741-742.
   PubMed     Text format    
   
   
10. DEVOS G, De Meerleer G, Joniau S
    Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?
    Eur Urol. 2019 Apr 25. pii: S0302-2838(19)30327.
    PubMed     Text format     Abstract available
    
    
11. SHARP A, Welti JC, Lambros MBK, Dolling D, et al
    Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Apr 27. pii: S0302-2838(19)30285.
    PubMed     Text format     Abstract available
    
    
12. FLETCHER CE
    The Role of Splicing Regulators in the Emergence of Treatment-induced Neuroendocrine Prostate Cancer: The Next Generation of Drug Targets?
    Eur Urol. 2019 Apr 29. pii: S0302-2838(19)30328.
    PubMed     Text format    
    
    

    
    Int J Radiat Oncol Biol Phys

13. SANDLER HM
    Responding to Information From Novel Positron Emission Tomography Imaging in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019;104:263-264.
    PubMed     Text format    
    
    
14. MENZEL P, Chang A
    Prostate-Specific Membrane Antigen Positron Emission Tomography-Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2019;104:261-262.
    PubMed     Text format    
    
    

    
    J Nucl Med

15. PIRON S, De Man K, Van Laeken N, D'Asseler Y, et al
    Radiation dosimetry and biodistribution of (18)F-PSMA-11 for PET imaging of prostate cancer.
    J Nucl Med. 2019 Apr 26. pii: jnumed.118.225250. doi: 10.2967/jnumed.118.225250.
    PubMed     Text format     Abstract available
    
    
16. HAMMES J, Tager P, Drzezga A
    EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT.
    J Nucl Med. 2017 Dec 14. pii: jnumed.117.203265. doi: 10.2967/jnumed.117.203265.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

17. TOSOIAN JJ, George AK
    Editorial Comment.
    J Urol. 2019;201:727.
    PubMed     Text format    
    
    
18. MORTEZAVI A, Krauter J, Gu DA, Sonderer J, et al
    Extensive histological sampling following focal therapy of clinically significant prostate cancer with high-intensity focused ultrasound.
    J Urol. 2019 May 1:101097JU0000000000000298. doi: 10.1097/JU.0000000000000298.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

19. CURSANO MC, Santini D, Iuliani M, Paganelli G, et al
    Early use of abiraterone and radium-223 in metastatic prostate cancer.
    Lancet Oncol. 2019;20:e228.
    PubMed     Text format    
    
    
20. HINDIE E, Morgat C
    Early use of abiraterone and radium-223 in metastatic prostate cancer.
    Lancet Oncol. 2019;20:e229.
    PubMed     Text format    
    
    

    
    Nat Rev Urol

21. THOMA C
    Targeting DLL3 in neuroendocrine prostate cancer.
    Nat Rev Urol. 2019 Apr 30. pii: 10.1038/s41585-019-0190.
    PubMed     Text format    
    
    
22. STONE L
    DDR pathway mediates radiosensitization in prostate cancer.
    Nat Rev Urol. 2019 Apr 26. pii: 10.1038/s41585-019-0188.
    PubMed     Text format    
    
    

    
    Oncogene

23. WANG C, Wang G, Feng X, Shepherd P, et al
    Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
    Oncogene. 2019;38:2451-2463.
    PubMed     Text format     Abstract available
    
    
24. ZHOU PJ, Wang X, An N, Wei L, et al
    Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes.
    Oncogene. 2019;38:2192-2205.
    PubMed     Text format     Abstract available
    
    
25. ZHU S, Tian H, Niu X, Wang J, et al
    Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
    Oncogene. 2019 May 2. pii: 10.1038/s41388-019-0827.
    PubMed     Text format     Abstract available
    
    
26. FLETCHER CE, Sulpice E, Combe S, Shibakawa A, et al
    Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.
    Oncogene. 2019 May 1. pii: 10.1038/s41388-019-0823.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

27. GARRIGUE P, Tang J, Ding L, Bouhlel A, et al
    Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors.
    Proc Natl Acad Sci U S A. 2018 Oct 22. pii: 1812938115.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

28. KURUL NO, Ates F, Yilmaz I, Narli G, et al
    The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
    Prostate. 2019 May 2. doi: 10.1002/pros.23825.
    PubMed     Text format     Abstract available
    
    
29. MCNAMARA MA, Oyekunle T, Chin BB, Oldan J, et al
    Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    Prostate. 2019 May 2. doi: 10.1002/pros.23822.
    PubMed     Text format     Abstract available
    
    
30. KRYVENKO ON, Wang Y, Sadasivan S, Gupta NS, et al
    Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.
    Prostate. 2019 May 2. doi: 10.1002/pros.23820.
    PubMed     Text format     Abstract available
    
    
31. HAN IH, Kim JH, Jang KS, Ryu JS, et al
    Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cells.
    Prostate. 2019 May 2. doi: 10.1002/pros.23826.
    PubMed     Text format     Abstract available
    
    

    
    Urol Int

32. FUJIMOTO N, Shiota M, Tomisaki I, Minato A, et al
    Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer.
    Urol Int. 2019 Apr 30:1-12. doi: 10.1159/000497280.
    PubMed     Text format     Abstract available
    
    

    
    Urology

33. MAY A, Henke J, Au D, Raza SJ, et al
    National trends in the utilization of androgen deprivation therapy for very low risk prostate cancer.
    Urology. 2019 Apr 29. pii: S0090-4295(19)30366.
    PubMed     Text format     Abstract available
    
    
34. MODI PK, Herrel LA, Kaufman SR, Yan P, et al
    Urologist practice structure and spending for prostate cancer care.
    Urology. 2019 Apr 25. pii: S0090-4295(19)30372.
    PubMed     Text format     Abstract available
    
    
35. PURYSKO AS
    Editorial comment.
    Urology. 2019;123:196-197.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: